HLS THERAPEUTICS INC (HLS.CA) Stock Price, Quote, News and Overview
TSX:HLS - Toronto Stock Exchange - CA40390B1094 - Common Stock - Currency: CAD
HLS.CA Quote, Performance and Key Statistics
TSX:HLS (6/16/2025, 7:00:00 PM)
4.99
+0.09 (+1.84%)
The current stock price of HLS.CA is 4.99 CAD. In the past month the price increased by 3.96%. In the past year, price increased by 45.27%.
HLS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.57 | 2.96B | ||
| CRON.CA | CRONOS GROUP INC | 14.5 | 1.01B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.28 | 752.86M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 54.73 | 599.77M | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 594.81M | ||
| ACB.CA | AURORA CANNABIS INC | 36.22 | 456.98M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 413.96M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 27.04 | 339.46M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | 32.33 | 259.73M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 255.28M | ||
| HITI.CA | HIGH TIDE INC | N/A | 243.93M | ||
| CRDL.CA | CARDIOL THERAPEUTICS INC-A | N/A | 159.44M |
Related stock screener links
About HLS.CA
Company Profile
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. The company is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.
Company Info
HLS THERAPEUTICS INC
10 Carlson Court, Suite 701
Etobicoke ONTARIO M9W 6L2 CA
CEO: Christopher Nutt
Employees: 92
Phone: 16474959000
HLS THERAPEUTICS INC / HLS.CA FAQ
What is the stock price of HLS THERAPEUTICS INC today?
The current stock price of HLS.CA is 4.99 CAD. The price increased by 1.84% in the last trading session.
What is the ticker symbol for HLS THERAPEUTICS INC stock?
The exchange symbol of HLS THERAPEUTICS INC is HLS and it is listed on the Toronto Stock Exchange exchange.
On which exchange is HLS.CA stock listed?
HLS.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for HLS THERAPEUTICS INC stock?
9 analysts have analysed HLS.CA and the average price target is 5.74 CAD. This implies a price increase of 14.98% is expected in the next year compared to the current price of 4.99. Check the HLS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HLS THERAPEUTICS INC worth?
HLS THERAPEUTICS INC (HLS.CA) has a market capitalization of 157.83M CAD. This makes HLS.CA a Micro Cap stock.
How many employees does HLS THERAPEUTICS INC have?
HLS THERAPEUTICS INC (HLS.CA) currently has 92 employees.
What are the support and resistance levels for HLS THERAPEUTICS INC (HLS.CA) stock?
HLS THERAPEUTICS INC (HLS.CA) has a support level at 4.95 and a resistance level at 5. Check the full technical report for a detailed analysis of HLS.CA support and resistance levels.
Is HLS THERAPEUTICS INC (HLS.CA) expected to grow?
The Revenue of HLS THERAPEUTICS INC (HLS.CA) is expected to grow by 1.06% in the next year. Check the estimates tab for more information on the HLS.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HLS THERAPEUTICS INC (HLS.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HLS.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HLS.CA, evaluating the profitability, health, valuation and growth aspects
- HLS THERAPEUTICS INC (HLS.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HLS THERAPEUTICS INC (HLS.CA) Sales and EPS estimates to see what analysts future expectations are.
- HLS THERAPEUTICS INC (HLS.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HLS THERAPEUTICS INC (HLS.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HLS THERAPEUTICS INC (HLS.CA) Stock Chart to make your own analysis
- HLS THERAPEUTICS INC (HLS.CA) Latest news and press-releases to stay up to date.
Does HLS THERAPEUTICS INC (HLS.CA) stock pay dividends?
HLS.CA does not pay a dividend.
When does HLS THERAPEUTICS INC (HLS.CA) report earnings?
HLS THERAPEUTICS INC (HLS.CA) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of HLS THERAPEUTICS INC (HLS.CA)?
HLS THERAPEUTICS INC (HLS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
HLS.CA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HLS.CA. When comparing the yearly performance of all stocks, HLS.CA is one of the better performing stocks in the market, outperforming 81.96% of all stocks.
HLS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA. The financial health of HLS.CA is average, but there are quite some concerns on its profitability.
HLS.CA Financial Highlights
Over the last trailing twelve months HLS.CA reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 33.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.68% | ||
| ROE | -26.92% | ||
| Debt/Equity | 0.87 |
HLS.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to HLS.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 52.22% and a revenue growth 1.06% for HLS.CA